AIRA Sciences is a multi-cancer early detection platform company that combines infrared spectroscopy with AI to identify cancer biomarkers from a simple cheek swab. Its lead product, AIR-DS Lung, is UKCA approved and supported by prospective clinical evidence in over 500 patients. The company is preparing for US LDT launch and FDA submission while expanding its product roadmap to address additional cancer indications.
Funding
Funding not disclosed
Founders
Product
Problem
Current lung cancer detection methods face significant challenges, including low patient compliance and high false positive rates due to benign nodules. Only 30% of cancers are detected before stage III, limiting early intervention opportunities and increasing mortality risk.
Solution
AIRA Sciences provides AIR-DS Lung, a non-invasive early detection device that uses infrared spectroscopy combined with AI to identify lung cancer biomarkers from a simple cheek swab. The platform eliminates the need for needles, discomfort, or genetic analysis, making cancer screening simple and accessible. The device is UKCA approved, ISO 13485 and IEC 62304 certified, and supported by prospective clinical evidence from over 500 patients. The company is currently running a multi-site UK clinical performance evaluation study while preparing for US LDT launch and FDA submission, with a roadmap to expand beyond lung cancer to other cancer indications.
Target Audience
Primary customers are healthcare systems, hospitals, and clinical laboratories seeking non-invasive cancer screening tools, as well as patients at risk for lung cancer who need accessible early detection options.
Features
- Non-invasive cheek swab sampling that requires no needles, discomfort, or genetic analysis
- Infrared spectroscopy technology combined with AI algorithms to detect cancer biomarkers
- UKCA approved and ISO 13485 and IEC 62304 certified medical device
- Equally accurate for stage I or stage IV cancer cases, enabling early detection
- Two granted global patent families protecting the core technology platform
- Care pathway optimization that reduces pressure on radiology departments with proven net monetary benefit